

Cover Story
Clinical
HRD results can vary widely, depending on what assay you choose—even as they guide treatment choices
Homologous recombination deficiency tests are used routinely in the clinic to determine which patients get PARP inhibitors.
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets
Trending Stories
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Montefiore Einstein Director Edward Chu dies of glioblastoma at 66
- Anthony Letai pledges to ensure stability for extramural and intramural cancer science
- Mary Pazdur, 63, Dies of Cancer; What Her Husband Has Learned
- Tidmarsh is out, Pazdur is in: FDA’s CDER under new leadership
















